tizonatx.comHealthcare / BioTech & PharmaFounded: 2015Funding to Date: $190.47MM
Tizona Therapeutics is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
01/03/2019 | Series B-3 | $15MM | $xx.xx | $173.78MM | Abbvie | |
Price per Share
$xx.xx
Shares Outstanding
9,375,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Abbvie
|
||||||
03/08/2016 | Series B-2 | $33.02MM | $xx.xx | $151.22MM | Abingworth, Amgen Ventures, Astellas Venture Management, Canaan Partners, Interwest Partners, Lightstone Ventures, Mpm Capital | |
Price per Share
$xx.xx
Shares Outstanding
30,018,169
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Abingworth, Amgen Ventures, Astellas Venture Management, Canaan Partners, Interwest Partners, Lightstone Ventures, Mpm Capital
|
||||||
03/08/2016 | Series B | $20MM | $xx.xx | $151.22MM | Abingworth, Amgen Ventures, Astellas Venture Management, Canaan Partners, Interwest Partners, Lightstone Ventures, Mpm Capital | |
Price per Share
$xx.xx
Shares Outstanding
13,333,332
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.4x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Abingworth, Amgen Ventures, Astellas Venture Management, Canaan Partners, Interwest Partners, Lightstone Ventures, Mpm Capital
|
||||||
01/10/2016 | Series A | $27.22MM | $xx.xx | $45.36MM | Amgen Ventures, Astellas Venture Management, Interwest Partner, Mpm Capital | |
Price per Share
$xx.xx
Shares Outstanding
27,217,500
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Amgen Ventures, Astellas Venture Management, Interwest Partner, Mpm Capital
|